New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis  by Deberg, Michelle et al.
OsteoArthritis and Cartilage (2005) 13, 258e265
ª 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.joca.2004.12.002New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for
studying oxidative-related type II collagen network degradation
in patients with osteoarthritis and rheumatoid arthritis
Michelle Deberg Ph.D.y, Alain Labasse Bc.S.y, Stephan Christgau Ph.D.z, Paul Cloos Ph.D.z,
Dennis Bang Henriksen Ph.D.z, Jean-Pierre Chapelle M.D., Ph.D.x, Brigitte Zegels Bc.S.y,
Jean-Yves Reginster M.D., Ph.D.y and Yves Henrotin Ph.D.yk{*
yBone and Cartilage Research Unit, University of Lie`ge, Sart Tilman, 4000 Lie`ge, Belgium
zNordic Bioscience, Herlev Hovedgade 207, Herlev, Denmark
xClinical Biology, CHU, Sart Tilman, 4000 Lie`ge, Belgium
kCentre for Immunology, CHU, Sart Tilman, 4000 Lie`ge, Belgium
{Centre for Oxygen Research and Development, CHU, Sart Tilman, 4000 Lie`ge, Belgium
Summary
Objective: Protein nitration is a prominent feature of inﬂammatory processes in the joint. We have developed immunoassays speciﬁc for
a peptide of the a-helical region of type II collagen 108HRGYPGLDG116 (Coll 2-1) and its nitrated form 108HRGY(NO2)PGLDG
116 (Coll 2-1
NO2) in biological ﬂuids.
Design: Coll 2-1 and Coll 2-1 NO2 peptides were injected into rabbits. Two antisera (D3 and D37) were selected for their speciﬁcity and afﬁnity
and used to develop speciﬁc immunoassays. Coll 2-1 and Coll 2-1 NO2 were measured in sera of 242 healthy subjects (N), 67 patients with
primary knee osteoarthritis (OA) and 19 patients with rheumatoid arthritis (RA).
Results: In healthy subjects, Coll 2-1 and Coll 2-1 NO2 concentrations were 125.13G 3.71 nM and 0.16G 0.08 nM, respectively. In OA and
RA, Coll 2-1 and Coll 2-1 NO2 serum levels were found to be signiﬁcantly increased compared to controls of the same range of age (Coll 2-1:
OA: 200.80G 8.98 nM, RA: 172.30G 19.05 nM, normal: 126.60G 6.70 nM and Coll 2-1 NO2: OA: 0.26G 0.02, RA: 0.38G 0.05, normal:
0.12G 0.01 nM). Coll 2-1 NO2 levels were signiﬁcantly more elevated in RA than in OA patients (P! 0.05). As a consequence, the ratio Coll
2-1 NO2/Coll 2-1 was 1.6 times higher in RA than in OA subjects. No relationship was found between the radiological OA severity and the
levels of Coll 2-1 and Coll 2-1 NO2 in serum. Coll 2-1 NO2, but not Coll 2-1, was correlated with C-reactive protein in the sera of OA and RA
patients.
Conclusions: The determination of both Coll 2-1 and Coll 2-1 NO2 in serum of arthritic patients seems to be a promising useful tool for the
detection of oxidative-related cartilage degradation episode. Further, these markers could be helpful for monitoring the effects of anti-
inﬂammatory or antioxidant drugs on cartilage degradation.
ª 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Type II collagen is the major structural protein in cartilage
and making up approximately 50% of the extracellular
cartilage matrix. In arthritis, type II collagen is enzymatically
and mechanically degraded and fragments are released into
synovial ﬂuid. Type II collagen-derived fragments have been
extensively investigated as potential markers of cartilage
remodelling in osteoarthritis (OA) and rheumatoid arthritis
(RA). Different strategies have been developed including the
measurement in biological ﬂuids and tissue explants of type
II collagen propeptides1e4 or degradation products5e9. Type
II collagen C-propeptide and N-propeptide, released extra-
cellularly from the newly synthesized molecule, have been
investigated as markers of type II collagen synthesis. Type II
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cartilage3,4. Type II collagen fragments released during
collagen processing are also present in circulation and can
be measured as markers of collagen degradation. To date,
different antibodies against degradation products of type II
collagen have been described in the literature5e9. Hollander
et al.5 have developed an immunoassay speciﬁc for the
peptide CB11B generated by cyanogen bromide cleavage of
the a1(II) chain. Another approach applied by Poole and co-
workers consisted in producing polyclonal antibodies di-
rected against neo-epitopes generated through cleavage of
type II collagen by interstitial collagenases6. These immuno-
assays were used for quantifying denaturated type II
collagen in cartilage after the enzymatic digestions of
biopsies. These studies concluded that type II collagen
denaturation is increased in OA cartilage and that collage-
nase activity plays a key role in this process5,6. In
contrast, the C2C neo-epitope did not vary in synovial ﬂuid
from patients with OA or with inﬂammatory joint diseases10.
Downs et al.8 have developed an enzyme-linked8
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neo-epitope of the 3/4 fragment of type II collagen generated
by collagenase cleavage. Urinary levels of this marker have
been reported to be 2.5 times higher in OA patients than in
healthy controls. Recently, Christgau et al.9 have described
an immunoassay speciﬁc for CartiLaps or CTX-II. Urinary
levels of this peptide are signiﬁcantly elevated in patients
with OA or RA compared with age-matched controls9. In OA,
urinary CTX-II correlated with minimal joint space width at
baseline and with increased rate of progression of joint
damage over 1 year4,11,12.
Peptide nitration is mainly caused by interaction of
aromatic amino acids with peroxynitrite anion (ONOO),
a strong oxidant formed by the reaction of nitric oxide (cNO)
and superoxide anion (O2
N). Tyrosine, phenylalanine and
tryptophan residues are particularly sensitive to nitration13.
As demonstrated for type I collagen, type II collagen is
susceptible of nitration by peroxynitrite14. High levels of
nitrite/nitrate have been found in the serum of patients with
OA and RA indicating that production of ONOO is
increased in these diseases15. Furthermore, chondrocytes
can produce both O2
N and cNO16e18 and nitrotyrosine has
been found in cartilage of arthritic patients19. It has also
been reported that N-iminoethyl-L-lysine, a selective in-
hibitor of the inducible nitric oxide synthase, reduces the
progression of experimental OA induced in dog20. Alto-
gether, these ﬁndings indicate that cNO or derived reactive
oxygen species play a major role in the structural changes
in arthritis and suggest that cartilage matrix components
can be nitrated in situ and thereafter released in the
synovial ﬂuid.
In this paper, we describe the development, technical
validation and clinical evaluation of two new immunoassays
for the measurements of type II collagen-derived
fragments. One assay was speciﬁc for the sequence
108HRGYPGLDG116 derived from the triple helical region
of type II collagen (Coll 2-1) and the other for its nitrated
form (Coll 2-1 NO2). The development of speciﬁc immuno-
assay for the measurement of nitrated type II collagen
fragments in biological ﬂuids seems relevant to study the
impact of the oxidative damage in cartilage pathophysiol-
ogy. These assays have been validated in serum of healthy
subjects and of patients with OA and RA.
Materials and methods
REAGENTS AND BUFFERS FOR IMMUNOASSAYS
All reagents were purchased from VWR and Sigma-
Aldrich unless otherwise stated. The coating buffer was
0.08 M NaHCO3, pH 9.6. The blocking buffer was com-
posed of 1.5 mM KH2PO4, 8 mM Na2HPO4, 2 mM KCl,
138 mM NaCl, 0.5% (w/v) bovine serum albumin (BSA),
5.3 g/100 ml lactose monohydrate, pH 7.2. The washing
buffer was a solution of 25 mM Tris, 50 mM NaCl, pH 7.3.
The standard curve and the dilution of samples, when it was
necessary, were done in 10 mM phosphate buffer saline
(PBS), 138 mM NaCl, 0.7% (w/v) BSA, 0.1% (v/v) Tween
20, pH 7.0, for the Coll 2-1 immunoassay and in 50 mM Tris,
138 mM NaCl, 0.7% (w/v) BSA, 0.1% (v/v) Tween 20, pH
8.0, for the Coll 2-1 NO2 immunoassay. The dilutions of the
antisera and of the secondary antibody were done in 10 mM
PBS, 138 mM NaCl, 0.2% (w/v) BSA, 0.1% (v/v) Tween 20,
pH 7.0, for the Coll 2-1 immunoassay and in 50 mM Tris,
138 mM NaCl, 0.2% (v/v) BSA, 0.1% (v/v) Tween 20, pH
8.0, for the Coll 2-1 NO2 immunoassay.COLL 2-1 AND COLL 2-1 NO2 SYNTHESIS
The peptide 108HRGYPGLDG116 (Coll 2-1) derived from
the a-helix of type II collagen (accession number in
GenBank: P02468) and its nitrated form 108HRGY
(NO2)PGLDG
116, Coll 2-1 NO2, were synthesized by
standard 9-ﬂuorenylmethyloxycarbonyle solid-phase pep-
tide synthesis (HBTU/HOBt protocol)21. Peptide purity was
conﬁrmed by reversed phase high performance liquid
chromatography (RP-HPLC), mass spectrometry and ami-
no acid analysis. The purity of both peptides exceeded 95%
as assessed by RP-HPLC analysis. These peptides were
conjugated to thyroglobulin by using glutaraldehyde as
linker22. The Coll 2-1 sequence is found only in type II and
XI collagens with 100% of homology. The sequence is not
found in other extracellular matrix proteins such as human
type I, III, VI and IX collagens, ﬁbronectin and aggrecan
(Swiss Prot and Blast databases).
IMMUNIZATION
Rabbits were injected intra-peritoneally with 1 ml of the
conjugated peptides (0.5 mg/ml) emulsiﬁed in equal vol-
umes with complete Freund’s adjuvant. Injections were
repeated four times every month using the same peptide
concentration as that of the ﬁrst injection in incomplete
Freund’s adjuvant. Ten days after the last injection, the
rabbits were sacriﬁced. Blood was drawn, allowed to clot for
30 min and centrifuged for 10 min at 2500 rpm at 4(C to
prepare serum. Serum was stored at 20(C until biomarker
measurement. Each month, a blood sample was taken and
the antiserum was screened by titration experiment for the
presence of anti-Coll 2-1 and anti-Coll 2-1 NO2 antibodies.
The antisera with the highest titres were selected for the
following experiments.
NITRATION OF NATIVE HUMAN TYPE I COLLAGEN, HUMAN
TYPE II COLLAGEN AND BSA MOLECULES
ONOO in alkaline solution was prepared from NaNO2
and H2O2 as previously described
23. To eliminate the
excess of H2O2, ONOO
 was treated with MnO2 and
ONOO concentration was determined spectrophotochemi-
cally at 302 nm (3Z 1700 M1 cm1). Stock solutions were
stored at 80(C. The nitration of human type I collagen
(Sigma-Aldrich), human type II collagen (puriﬁed according
to the method described in Henrotin et al.24) and BSA was
performed as follows: 1.6 mg of protein was dissolved in
1 ml of 10 mM PBS, pH 7.4, containing 1 mM Fe3C
ethylenediaminetetraacetic acid (EDTA) and mixed rapidly
with 2 mM ONOO (ﬁnal concentration). This procedure
allowed the optimal nitration (nitration veriﬁed by an ELISA
speciﬁc for nitrotyrosine, TCS CellWorks Ltd, UK) of the
molecules without damaging their structure as demonstrat-
ed by sodium dodecyl sulphateepolyacrylamide gel elec-
trophoresis (SDS-PAGE) (data not shown).
ANTISERUM SPECIFICITY
The speciﬁcity/cross-reactivity of the two selected anti-
sera (D3 and D37) was investigated by competitive
inhibitions procedure. Coll 2-1, Coll 2-1 NO2, native human
type I and II collagens, human nitrated type I and II
collagens, human heat denatured type I and II collagens
(obtained by heating a solution of native human type I and II
collagens at 100(C for 30 min), BSA, nitrated BSA and 3-
nitro-L-tyrosine residue were used as competitors. Brieﬂy,
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the antigen (Coll 2-1 or Coll 2-1 NO2) both conjugated to
BSA by Bis[sulfosuccinimidyl] suberate (BS3) (40 ng/
100 ml). After washing, the plates were blocked with 400 ml
of saturation buffer at room temperature. Fifty microlitres of
buffer with or without the different competitors at increasing
concentrations (from 105 to 1011 M) and 100 ml of
antiserum diluted to obtain 1.5 of optical density were
incubated for 1 h at room temperature. Microplates were
then washed, 100 ml of a goat antibody conjugated to
horseradish peroxidase (Biosource Europe), diluted at 1/
5000, was added and incubated for 1 h at room tempera-
ture. After washing, 100 ml of freshly prepared enzyme
substrate [3,3#,5,5#-tetramethylbenzidine (TMB), Biosource
Europe] was added into each well. The reaction was
stopped with 100 ml of H3PO4 4 M. The colouration was
read at 450 nm, corrected for absorbance at 650 nm.
IMMUNOASSAY FOR COLL 2-1 PEPTIDE
Coll 2-1 conjugated to BSA by BS3 was coated by adding
100 ml of a solution at 50 ng/ml for 48 h at 4(C. Microtitre
plates were subsequently blocked with 400 ml/well of
blocking buffer for 90 min at room temperature. Fifty
microlitres of calibrators (synthetic peptide) or unknown
samples were applied to the wells, followed by 100 ml of D3
antibody, diluted 1/40,000, and incubated for 1 h at room
temperature. During the procedure, a competition for
binding the antibody takes place between the immobilized
peptide and the peptide contained in the samples. After
washing, 100 ml of peroxidase-conjugated goat antibodies
to rabbit IgG (Biosource Europe), diluted 1/5000, were
incubated for 1 h at room temperature. After washing,
100 ml of freshly prepared enzyme substrate (TMB, Bio-
source Europe) was added into each well. After 15 min, the
reaction was stopped with 100 ml of 4 M H3PO4. The
colouration was read with a microplate reader (Labsystem)
at 450 nm, corrected for absorbance at 650 nm.
IMMUNOASSAY FOR COLL 2-1 NO2
Coll 2-1 NO2 was conjugated to biotin according to the
method described by Rosenquist et al.25. One hundred
microlitres of this biotinylated peptide at 1.25 ng/ml was
added to each well of streptavidine-coated plates (Exiqon,
Denmark) and incubated for 1 h at room temperature. Fifty
microlitres of calibrators or unknown samples and 100 ml of
D37, diluted 1/500,000, were distributed in 96-well plate and
incubated for 1 h at room temperature. The detection of the
antibody bound and the revelation were realized using the
same procedure that described for Coll 2-1 immunoassay.
EXPERIMENTAL POPULATIONS
To establish reference values for Coll 2-1 and Coll 2-1
NO2, sera were collected from 242 healthy ambulatory
subjects attending a blood donor centre, none of whom was
subjected to bone radiological and/or scintigraphy and none
of whom had any evidence of arthritis or other inﬂammatory
disease. None was currently taking any medication known
to modify arthritic disease or inﬂuence joint metabolism.
This group was composed by 170 men and 72 women,
aged from 20 to 65 years (meanGSD: 41.8G 13.0 years).
Women were aged 42.7G 10.4 years and men 42.8G 14.5
years. Sera of 67 successive patients (47 women and 20
men aged over 45 years, meanG SD: 65.0G 20.1 years)with knee OA diagnosed according to the clinical and
radiological criteria of the American College of Rheumatol-
ogy (ACR) were collected. Disease severity was graded on
the basis of Kellgren and Lawrence radiographic system.
The OA population was mainly composed of patients with
grade 2 (4/67 had a grade 1, 45/67 had a grade 2, 15/67 had
a grade 3 and 3/67 had a grade 4). All subjects had a normal
leukocytosis. None of these patients were taking any
potential structure modifying drugs. Coll 2-1 and Coll 2-1
NO2 concentrations were also measured in serum samples
of patients with RA (nZ 19). The RA patients (three men,
16 women) had an average age of 60 years (meanG SD:
59.6G 12.6 years) and an average disease duration of 8
years and all had active disease at the sampling time
[according to the ACR criteria of RA (revised 1987 criteria)].
The RA patients did not receive glucocorticoids but were
treated with Non Steroidal Anti-Inﬂammatory Drugs or
Disease Modifying Anti-Rheumatic Drugs i.e., methotrexate.
For all the participants, serum levels of C-reactive protein
(CRP) were measured by a highly sensitive CRP assay
(Berhing, Marburg, Germany).
All study subjects gave their written informed consent to
participate, and the studies were approved by the ethical
committee of the University of Lie`ge.
STATISTICAL METHODS
Statistical studies were performed using SPSS software
version 11.0 software (SPSS, sigma Stat) and S-PLUS
6.2 for windows. The Coll 2-1 and Coll 2-1 NO2 values in the
different groups of patients were expressed as meanG
S.E.M. The Coll 2-1 NO2/Coll 2-1 ratio was also calculated.
The non-parametric ManneWhitney U test was used to
compare the OA or RA patients and healthy subjects of the
same range of age. To determine the inﬂuence of gender
and ageing on Coll 2-1, Coll 2-1 NO2 concentrations and
Coll 2-1 NO2/Coll 2-1 ratio, we performed a regression
analysis. To ﬁnd which subclasses of age of healthy
subjects were different to the others, we realized an
analysis of one-way variance. The correlations between
the CRP and the two markers and between the two markers
were estimated by the non-parametric Spearman’s rank
correlation coefﬁcient. Data were considered statistically
signiﬁcant when P value was below 0.05 (two-tailed test).
Results
ANTISERUM SPECIFICITY
Two antisera, D3 and D37, with a high speciﬁcity for Coll
2-1 and Coll 2-1 NO2, respectively, were identiﬁed. D3 did
not recognize human native type I and II collagens, human
heat denatured type I and II collagens, and BSA suggesting
that D3 was speciﬁc for the linear form of Coll 2-1 [Fig. 1(A)].
D3 also recognized, with the same afﬁnity, the nitrated form
of Coll 2-1.
D37 showed a high afﬁnity for Coll 2-1 NO2. Thus, the
cross-reactivity of non-nitrated peptide (Coll 2-1) and
human nitrated type II collagen with D37 was calculated
to 0.02% and less than 0.08%, respectively. Furthermore,
D37 did not recognize human nitrated type I collagen,
native human type I and II collagens, nitrated BSA, BSA
and 3-nitro-L-tyrosine residue [Fig. 1(B)]. The very high
concentrations of Coll 2-1 and nitrated collagen type II
needed to displace the Coll 2-1 NO2/D37 binding suggested
that D37 was speciﬁc for Coll 2-1 NO2.
261Osteoarthritis and Cartilage Vol. 13, No. 3Fig. 1. Competitive inhibitions of D3 and D37. Competitive inhibitions of (A) D3 with Coll 2-1 (C), Coll 2-1 NO2 (B), native type II collagen (A),
type I collagen (:), denatured type II collagen ( ), denatured type I collagen ( ) and BSA (;) and (B) D37 with Coll 2-1 (C), Coll 2-1 NO2
(B), type II collagen (A), nitrated type II collagen (>), type I collagen (:), nitrated type I collagen (6), BSA (;), nitrated BSA (7) and 3-
nitro-L-tyrosine ( ). B/B0 represents the ratio of coated antigen bound in the presence of free antigen to the coated antigen bound in the
absence of free antigen.ASSAYS CHARACTERISTICS
ELISA for Coll 2-1 peptide
The lower detection limit of the assay, deﬁned as the
concentration corresponding to three SD above the mean of
10 determinations of the zero calibrator, was 17 nM. The
working range of this assay was established by calculating
the coefﬁcients of variation (CVs) of each calibrator in 10
independent calibration curves. CVs were below 10%
between 2000 and 10 nM. The within-run (intra-assay)
precision, assessed by measuring three serum samples 10
times in the same run, and the between-run (inter-assay)
precision, determined from the same samples (nZ 3)
assayed on 10 plates, were below 10% (Table I). Linearity
was shown by diluting the samples serially and comparing
the observed values with those expected. Typical recovery
rate of 92.0e109.3% was noted in a range of dilution
between 2 and 16 fold (Table II). Spiking recovery,
determined by addition of known quantities of Coll 2-1peptide (from 25 to 500 nM) into sera ranged from 101.8%
to 106.5% (Table III).
ELISA for Coll 2-1 NO2 peptide
The limit of detection of Coll 2-1 NO2 assay was 25 pM
and the working range was between 0.01 and 10 nM. In
serum (nZ 3), the intra- and inter-assays CVs were less
than 10% (Table I). The dilution curves of sera were parallel
to the standard curve (Table II). The spike recovery of Coll
2-1 NO2 in sera was between 106.2% and 132.2% (Table
III).
COLL 2-1 AND COLL 2-1 NO2 LEVELS IN SERA OF HEALTHY,
OA AND RA SUBJECTS
The mean concentrations of Coll 2-1 and Coll 2-1 NO2 in
the serum of normal subjects (nZ 242) were 125.13G
3.71 nM and 0.16G 0.08 nM, respectively. By a regressionTable I
Assay imprecision of Coll 2-1 and Coll 2-1 NO2 immunoassays in serum
Sample Intra-assay Sample Inter-assay
Coll 2-1 concentration (meanGSD) (nM) CV (%) Coll 2-1 concentration (meanGSD) (nM) CV (%)
Coll 2-1 assay
1 95.07G 7.2 7.6 1 112.84G 10.49 9.3
2 109.86G 9.11 8.3 2 123.08G 11.69 9.5
3 173.48G 15.09 8.7 3 184.16G 16.57 9.0
Average 8.2 Average 9.3
Coll 2-1 NO2 assay
Coll 2-1 NO2 concentration (meanGSD) (nM) Coll 2-1 NO2 concentration (meanG SD) (nM)
1 0.14G 0.01 8.6 1 0.14G 0.01 8.9
2 0.17G 0.01 6.6 2 0.16G 0.01 10.1
3 0.39G 0.02 5.4 3 1.61G 0.17 10.7
Average 6.9 Average 9.9
262 M. Deberg et al.: Immunoassays for type II collagen breakdown productsanalysis, we observed that neither the age and nor the
gender modiﬁed the Coll 2-1 serum level. In contrast, Coll 2-
1 NO2 concentration and the Coll 2-1 NO2/Coll 2-1 ratio
decreased with the age (P! 0.001). When the population
was stratiﬁed by age in 5-year brackets, Coll 2-1 serum
level did not vary signiﬁcantly between the age groups
(20e65 years) [Fig. 2(A)]. In contrast, the level of Coll 2-1
NO2 and the ratio Coll 2-1 NO2/Coll 2-1 of the group 26e30
years were signiﬁcantly higher than in the older groups (Coll
2-1 NO2: 0.0001!P! 0.05 and Coll 2-1 NO2/Coll 2-1:
0.0001!P! 0.05) [Fig. 2(B and C)]. When subjects aged
from 46 to 55 years corresponding to the early post-
menopausal women were removed, Coll 2-1 NO2 level was
higher (PZ 0.003) in premenopausal women (aged under
46 years and with regular menstruation) (0.22G 0.02 nM)
than in late postmenopausal women (aged above 55 years)
(0.12G 0.01 nM). Furthermore, in individuals younger than
45 years, Coll 2-1 NO2 serum levels were signiﬁcantly
higher in women than in men (0.22G 0.02 nM vs
0.16G 0.01 nM, PZ 0.003), whereas levels are identical
in both sexes after 55 years old (0.12G 0.01 nM vs
0.12G 0.01 nM). No signiﬁcant correlation was observed
between Coll 2-1 and Coll 2-1 NO2 concentrations in
healthy subjects aged from 20 to 65 years (rZ0.10).
In comparison with healthy subjects of the same range of
age, Coll 2-1 concentration was 1.6 and 1.4 times higher in
OA patients (P! 0.001) and in RA patients (P! 0.05),
respectively (normal: 126.60G 6.70 nM, OA: 200.80G
8.98 nM and RA: 172.30G 19.05 nM). Coll 2-1 NO2
concentration doubled in OA patients (P! 0.001) and
was increased by 3.2 times (P! 0.001) in RA patients
compared to the healthy subjects (OA: 0.26G 0.02, RA:
0.38G 0.05 and normal: 0.12G 0.01 nM) [Fig. 3(A and B)].
The ratio Coll 2-1 NO2/Coll 2-1 was increased in both OA
and RA subjects, but to a lesser extent in OA. In healthy
population, the mean ratio Coll 2-1 NO2/Coll 2-1 value was
Table II
Dilution test of three serum samples in Coll 2-1 and Coll 2-1 NO2
immunoassays
Dilution A B C
Coll 2-1 in serum, nM (%)*
1:2 597.30 (99.5) 684.91 (93.8) 785.29 (98.0)
1:4 282.80 (94.3) 340.53 (93.3) 373.01 (93.3)
1:8 139.95 (93.3) 176.59 (96.7) 196.60 (98.3)
1:16 81.98 (109.3) 84.01 (92.0) 93.10 (93.2)
Coll 2-1 NO2 in serum, nM (%)*
1:2 0.52 (100) 1.06 (91.4) 0.12 (92.3)
1:4 0.27 (103.8) 0.62 (106.9) 0.06 (92.3)
1:8 0.10 (76.9) 0.35 (120.7) e
*Undiluted sampleZ 100%.0.13G 0.02 but it increased to 0.15G 0.01 in OA and
0.25G 0.03 in RA (normal vs OA, PZ 0.03; normal vs RA,
P! 0.001; OA vs RA, P! 0.001) [Fig. 3(C)]. We have also
studied the relationship between the levels of Coll 2-1 and
Fig. 2. Concentrations of Coll 2-1 (A) and Coll 2-1 NO2 (B) and ratio
Coll 2-1 NO2/Coll 2-1 (C) in 242 healthy subjects aged from 20 to 65
years and stratiﬁed by 5 years. Results were expressed as
meanG S.E.M. The concentration of Coll 2-1 NO2 and the ratio Coll
2-1 NO2/Coll 2-1 of the subclass 26e30 are different to those of the
subclasses 36e40, 46e50, 51e55, 56e60, 61e65 years. Statis-
tical analysis was performed by an analysis of one-way variance:
*P! 0.05; **P! 0.01; ***P! 0.001.Table III
Analytical recovery of Coll 2-1 and Coll 2-1 NO2 added to serum samples. The concentration range in the unspiked samples was 81e500 nM
and 0.05e0.15 nM for Coll 2-1 and Coll 2-1 NO2, respectively
Coll 2-1 assay Coll 2-1 NO2 assay
Added peptide (nM) Recovery (%) (meanG SD) Added peptide (nM) Recovery (%) (meanG SD)
C0 e C0.00 e
C25 104.9G 0.0 C0.10 106.2G 6.0
C50 105.6G 9.2 C0.25 119.4G 18.7
C100 106.5G 26.1 C0.50 129.3G 27.6
C500 101.8G 5.0 C1.00 132.2G 21.8
Average 104.7 Average 121.9
263Osteoarthritis and Cartilage Vol. 13, No. 3Coll 2-1 NO2 in serum and radiological severity of knee OA
graded according the Kellgren and Lawrence scale (noted
1e4). Whatever the severity of OA radiological lesions, Coll
2-1 and Coll 2-1 NO2 were elevated in OA patients
compared to healthy subjects (P! 0.05), but there was
no signiﬁcant difference between Kellgren and Lawrence
subgroups (data not shown). In OA and RA populations,
Coll 2-1 NO2, but not Coll 2-1, was signiﬁcantly correlated
(OA: rZ 0.27; RA: rZ 0.23, P! 0.05) with the CRP values,
indicating that Coll 2-1 nitration is related to the intensity of
inﬂammatory reaction.
Fig. 3. Individual values of serum Coll 2-1 (A), Coll 2-1 NO2 (B) and
of the ratio Coll 2-1 NO2/Coll 2-1 (C), in 67 OA, in 19 RA patients
and in 80 age-matched healthy subjects. Statistical analysis was
performed by the non-parametric ManneWhitney U test: *P! 0.05;
***P! 0.001.Discussion
Here, we described two novel immunoassays, one
speciﬁc for a peptide derived from the triple helical part of
the type II collagen molecule (Coll 2-1) and the other for its
nitrated form (Coll 2-1 NO2). We selected this peptide-
sequence because it contains a tyrosine residue susceptible
for nitration. Interestingly, phenylalanine and tryptophan, two
other aromatic residues sensitive to nitration, were absent of
our selected peptide. Chondrocytes express both nicotin-
amide adenine dinucleotide phosphate oxidase and cNO
synthases16,26 and can produce high levels of cNO and O2
N
in pathological conditions19. As it is now well accepted that
oxidative damage is involved in cartilage matrix degrada-
tion27, we have anticipated that nitrated Coll 2-1 could reﬂect
the oxidative-related cartilage degradation.
A systematic research of the Coll 2-1 amino acids
sequence in Swiss Prot and Blast databases revealed that
the Coll 2-1 peptide is only found in the a1 chain of type II
collagen and in the a3 chain of type XI collagen. Both
collagen types are very speciﬁc to cartilage and are only
found in trace amounts in other tissues. Moreover, type XI
collagen makes up only about 1% wt/wt relative to a1(II)
chain28 suggesting that the contribution of type XI collagen
in our immunoassays is probably minor. Type XI collagen is
embedded in the type II collagen ﬁbrils and its processing
occurs with type II collagen. Therefore, we can hypothesize
that Coll 2-1 fragments are simultaneously released from
type II and XI collagens and that they reﬂect the
degradation of cartilage matrix.
Based on these considerations, we have developed two
immunoassays for measuring Coll 2-1 and Coll 2-1 NO2 in
serum. These immunoassays have a good performance
with respect to precision, recovery, linearity and speciﬁcity.
The antisera D3 is speciﬁc for the sequence Coll 2-1 and
does not cross-react with any other collagen or protein
tested in this study in spite of a 66% sequence homology
with the a(2) chain of type I collagen. In parallel, we have
developed an immunoassay for the nitrated form of Coll 2-1.
Despite a very low cross-reactivity (!0.1%) with Coll 2-1
and nitrated type II collagen, the antiserum (D37) can be
considered as speciﬁc for Coll 2-1 NO2. It does not cross-
react with the other nitrated proteins and with free tyrosine
residues. With regards to the long-term handling and
assaying of the serum samples, we have shown that type
II collagen a-helix fragments (Coll 2-1 and Coll 2-1 NO2)
resisted at least at ﬁve freezeethaw cycles. Moreover, lipids,
haemoglobin and bilirubin (concentrations up to 5 g/L,
200 mM and 250 mM, respectively) do not interfere with Coll
2-1 and Coll 2-1 NO2 measurements in serum (data not
shown). These ﬁndings are important for potential applica-
tions of the marker in a routine clinical laboratory.
The current assays were further characterized by
analysing sera from different groups of subjects. In normal
subjects, whatever the gender, Coll 2-1 concentrations
remain relatively constant from age 20e65 suggesting that
Coll 2-1 increase in arthritic patients is not the conse-
quence of ageing but reﬂects disease process. In contrast,
Coll 2-1 NO2 level was more elevated in the younger
subjects. This elevation could be explained by the more
intensive professional and sport activities performed by
subjects of this group. Coll 2-1 NO2 levels are higher in
premenopausal women than in men of the same range of
age whereas Coll 2-1 levels are similar in both sexes. The
increased level of Coll 2-1 NO2 in premenopausal women
suggests that Coll 2-1 nitration is associated with oestrogen
levels. This hypothesis is supported by previous studies
264 M. Deberg et al.: Immunoassays for type II collagen breakdown productsdemonstrating that nitrite/nitrate plasma levels were posi-
tively correlated with 17b-oestradiol levels in pre- and
postmenopausal women and that hormone replacement
therapy increased NO2
/NO3
 levels29. Nevertheless, further
in vitro and in vivo investigations are needed before
concluding on the role played by oestrogens on cartilage
matrix nitration.
We have also observed that the Coll 2-1 concentration is
signiﬁcantly increased in serum of OA patients compared to
healthy controls, indicating that the rate of type II collagen
degradation is increased in OA. This ﬁnding corroborates
previous studies demonstrating an increase of type II
collagen breakdown products in urine9, synovial ﬂuid30
and cartilage explants6 of OA patients. Interestingly, in OA
and RA populations, Coll 2-1 NO2, but not Coll 2-1, was
signiﬁcantly correlated with CRP levels. Although we
cannot exclude an extra-articular nitration of Coll 2-1, these
ﬁndings suggest that Coll 2-1 peptide nitration is directly
related to synovium inﬂammation and that Coll 2-1 NO2
could be a promising marker of arthritic disease activity.
However, we are aware that our study has some limitations.
The clinical data represent quite small OA and RA cohorts
and the clinical performance of these markers will require
additional validation in larger clinical studies. However, the
determination of Coll 2-1, a speciﬁc peptide of cartilage, and
its nitrated form in biological ﬂuids or chondrocytes-
conditioned culture medium has the potential to be a useful
tool in understanding the role of reactive nitrogen species in
cartilage homeostasis and degradation.
In conclusion, we have designed two immunoassays for
quantifying in serum a fragment derived from the triple helix
of type II collagen in its native and nitrated form. These
assays could be useful to elucidate type II collagen
degradation and oxidative damages in inﬂammatory joint
diseases.
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